Clinical Trial Update: Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing feasibility and efficacy of Durvalumab+Tremelimumab+radiation therapy and Durvalumab+radiation therapy in non-resectable locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Ulrich Keilholz | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED